Patents Assigned to DiagnoCure, Inc.
-
Publication number: 20150218646Abstract: The present invention relates to prostate cancer signatures which are useful for providing a clinical assessment of prostate cancer from a biological sample of a subject. By performing initial gene expression studies on urine samples from prostate cancer and non-prostate cancer subjects, and using the PCA3/PSA prostate cancer test as a performance benchmark, the present inventors have surprisingly discovered multiple signatures that are informative in urine-based prostate cancer tests, as well as in tissue-based tests. The signatures relate to combinations of at least two prostate cancer markers whose expression pattern in urine has been validated as being associated (either positively or negatively) with a clinical assessment of prostate cancer. The prostate cancer markers can be used in conjunction with bioinformatics approaches to generate a prostate cancer score, which correlates with a clinical assessment of prostate cancer.Type: ApplicationFiled: June 14, 2013Publication date: August 6, 2015Applicant: DIAGNOCURE INCInventors: Jean-François Haince, Guillaume Beaudry, Yves Fradet, Éric Paquet
-
Publication number: 20140087384Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.Type: ApplicationFiled: November 20, 2013Publication date: March 27, 2014Applicant: DiagnoCure Inc.Inventors: Ursula Busse, Camille Chypre, Yves Fradet
-
Patent number: 8618276Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.Type: GrantFiled: August 2, 2012Date of Patent: December 31, 2013Assignee: DiagnoCure Inc.Inventors: Ursula Busse, Camille Chypre, Yves Fradet
-
Publication number: 20130344487Abstract: The present invention provides methods to detect prostate cancer by detecting the RNA encoded by PCA3. The disclosure provides a method for determining a predisposition, or presence of prostate cancer comprising: (a) contacting a sample with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting an amount of PCA3 and second prostate-specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and determining the presence or absence of prostate cancer. Diagnostic kits are provided for detecting prostate cancer or the risk of developing same comprising: (a) at least one container means containing at least one oligonucleotide probe or primer that hybridizes to PCA3 (b) at least one oligonucleotide probe or primer that hybridizes with a second prostate specific nucleic acid; and (c) reagents for detecting PCA3 and the second prostate specific nucleic acid.Type: ApplicationFiled: August 28, 2013Publication date: December 26, 2013Applicant: DiagnoCure Inc.Inventors: Yves Fradet, Camille Chypre, Lyson Piche, Genevieve Garon
-
Patent number: 8546551Abstract: The present invention provides methods to detect prostate cancer by detecting the RNA encoded by PCA3. The disclosure provides a method for determining a predisposition, or presence of prostate cancer comprising: (a) contacting a sample with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting an amount of PCA3 and second prostate-specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and determining the presence or absence of prostate cancer. Diagnostic kits are provided for detecting prostate cancer or the risk of developing same comprising: (a) at least one container means containing at least one oligonucleotide probe or primer that hybridizes to PCA3 (b) at least one oligonucleotide probe or primer that hybridizes with a second prostate specific nucleic acid; and (c) reagents for detecting PCA3 and the second prostate specific nucleic acid.Type: GrantFiled: May 14, 2012Date of Patent: October 1, 2013Assignee: DiagnoCure Inc.Inventors: Yves Fradet, Camille Chypre, Lyson Piché, Geneviève Garon
-
Patent number: 8241848Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.Type: GrantFiled: April 5, 2011Date of Patent: August 14, 2012Assignee: DiagnoCure Inc.Inventors: Ursula Busse, Camille Chypre, Yves Fradet
-
Patent number: 8192931Abstract: The present invention relates to prostate cancer. More specifically, the present invention relates to a method to detect prostate cancer in a patient sample by detecting the RNA encoded by the gene PCA3. More particularly the present invention relates to a method for determining a predisposition, or presence of prostate cancer in a patient comprising: (a) contacting a biological sample of a patient with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting in the biological sample an amount of PCA3 and second prostate specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and therefrom determining the presence or absence of prostate cancer in the biological sample.Type: GrantFiled: July 10, 2009Date of Patent: June 5, 2012Assignee: DiagnoCure Inc.Inventors: Yves Fradet, Camille Chypre, Lyson Piché, Geneviéve Garon
-
Publication number: 20110306055Abstract: The present invention provides a novel method for diagnosing, monitoring, prognosing and staging Lymph Node (LN) status in colorectal cancer (CRC) that is more sensitive and accurate than conventional detection technologies such as histopathology. The Guanylyl Cyclase C (GCC) gene is specifically expressed in apical epithelial cells of the GI tract from the duodenum to the rectum and the detection of GCC mRNA in LNs is indicative of the presence of metastases. Quantitative RT-PCR (RT-qPCR) detection of GCC mRNA to identify the presence of colorectal cancer (CRC) cells in LNs has the potential to aid in CRC staging. When used in combination with glucuronidase B (GUSB), accurate quantification of GCC can be achieved with less than a 2-fold variation between intact and highly degraded RNA specimens.Type: ApplicationFiled: February 24, 2010Publication date: December 15, 2011Applicant: DIAGNOCURE INC.Inventors: Jean-Francois Haince, Guillaume Beaudry, Genevieve Garon, Michel Houde, Timothy J. Holzer, Martin Beaulieu, Nicolas Bertrand
-
Patent number: 7927806Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.Type: GrantFiled: December 11, 2009Date of Patent: April 19, 2011Assignee: Diagnocure Inc.Inventors: Ursula Busse, Camille Chypre, Yves Fradet
-
Patent number: 7655408Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.Type: GrantFiled: April 7, 2008Date of Patent: February 2, 2010Assignee: Diagnocure Inc.Inventors: Ursula Busse, Camille Chypre, Yves Fradet
-
Patent number: 7368545Abstract: This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostrate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.Type: GrantFiled: September 29, 2000Date of Patent: May 6, 2008Assignee: DiagnoCure Inc.Inventors: Ursula Busse, Camille Chypre, Yves Fradet
-
Patent number: 6197935Abstract: The use of collagen as a biomedical implant raises safety issues towards viruses and prions. The physicochemical changes and the in vitro and in vivo biocompatibility of collagen treated with heat, and by formic acid (FA), trifluoroacetic acid (TFA), tetrafluoroethanol (TFE) and hexafluoroiso-propanol (HFIP) were investigated. FA and TFA resulted in extensive depurination of nucleic acids while HFIP and TFE did so to a lesser degree. The molecules of FA, and most importantly of TFA, remained within collagen. Although these two acids induced modification in the secondary structure of collagen, resistance to collagenase was not affected and, in vitro, cell growth was not impaired. Severe dehydrothermal treatment, for example 110° C. for 1-3 days under high vacuum, also succeeded in removing completely nucleic acids. Since this treatment also leads to slight cross-linking, it could be advantageously used to eliminate prion and to stabilize gelatin products.Type: GrantFiled: September 29, 1998Date of Patent: March 6, 2001Assignee: DiagnoCure, Inc.Inventors: Charles Doillon, Régen Drouin, Gaétan LaRoche